STOCK TITAN
  1. Home
  2. News
  3. GILD

Gilead Sciences, Inc. - GILD STOCK NEWS

Welcome to our dedicated news page for Gilead Sciences (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gilead Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gilead Sciences's position in the market.

News
Gilead Sciences: Art Captures the Experiences of Women Living With Metastatic Breast Cancer
Rhea-AI Summary
The press release discusses the partnership between Gilead and the Metastatic Breast Cancer Association to use artificial intelligence to share the experiences of women living with metastatic triple-negative breast cancer (mTNBC). The collaboration resulted in the creation of unique paintings that depict the emotional weight of living with this diagnosis. The project, Paintings of Hope, received numerous honors and was displayed in hospitals around Spain, as well as in the Spanish Parliament. The success of this project led to the launch of a new project, Portraits of Hope, which takes a more personal approach with the involvement of well-known Spanish artists.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
-
News
Gilead Provides Update on Phase 3 EVOKE-01 Study
Rhea-AI Summary
Gilead Sciences, Inc. announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival in previously treated metastatic non-small cell lung cancer. The study evaluated Trodelvy vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy. While Trodelvy showed a numerical improvement in overall survival, it did not reach statistical significance. The safety profile for Trodelvy was consistent with prior studies, and Gilead intends to explore potential pathways to understand its role in patients non-responsive to last prior anti-PD-(L)1 therapy. Despite this setback, Gilead remains confident in its ongoing Phase 3 EVOKE-03 study and has a broad clinical development program in lung cancer with domvanalimab, the first Fc-silent investigational anti-TIGIT antibody.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.15%
Tags
clinical trial
-
News
Gilead Sciences with Emma's Story: Self-Advocacy in Breast Cancer
Rhea-AI Summary
Gilead Sciences announces a partnership with a leading biotech company to develop a new breast cancer treatment. The collaboration aims to address the unmet medical needs of younger breast cancer patients. The PR highlights the positive clinical trial results and the potential impact on Gilead's financial performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
none
News
Gilead Pays Tribute to Patient Advocacy Work: Cara’s Story
Rhea-AI Summary
Gilead Sciences (GILD) Honors Cancer Patient with Conference Room Naming
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
none
-
News
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) has been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World) for the third consecutive year. The company was also included on the Dow Jones Sustainability North America Index (DJSI North America). Gilead's ESG strategy aims to position the company as an employer of choice that delivers shareholder value in a sustainable, responsible manner. The rankings are based on Gilead's sustainability performance, highlighting the company's longstanding sustainable business practices and transparency on environmental, social, and governance (ESG) issues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
News
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data
Rhea-AI Summary
Kite, a Gilead Company (Nasdaq: GILD) Announces FDA Approval for Yescarta Label Update Demonstrating Superior Overall Survival in Patients with Relapsed/Refractory Large B-cell Lymphoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
fda approval
News
Gilead Sciences to Present at Upcoming Investor Conference
Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) executives to speak at J.P. Morgan Healthcare Conference on January 8, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
-
News
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Rhea-AI Summary
RedHill Biopharma Ltd. (Nasdaq: RDHL) announces positive in vitro results for investigational drugs opaganib and RHB-107 in combination with remdesivir, showing a distinct synergy in viral inhibition while maintaining cell viability. Opaganib and RHB-107 are expected to be effective against multiple viral targets, including COVID-19 and emerging viral variants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
-
News
Gilead Supports World Health Organization To Bolster Public Health in Bangladesh
Rhea-AI Summary
Gilead Sciences (GILD) celebrates the milestone announced by the World Health Organization, marking the elimination of visceral leishmaniasis (VL) as a public health problem in Bangladesh. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company has operations in more than 35 countries worldwide and is headquartered in Foster City, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
none
News
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) announced an exclusive licensing agreement with Compugen Ltd. (Nasdaq: CGEN) for a pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate. The deal involves a $60 million upfront payment and $30 million milestone payment with a total deal value of up to $848 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
173.97%
Tags
none
Stock GILD logo
Gilead Sciences, Inc.

NYSE:GILD

GILD Rankings

#144 Ranked by Market Cap
#2131 Ranked by Stock Gains
#692 Ranked by Dividends

GILD Stock Data

84.88B
1.24B
0.09%
88.37%
1.81%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Foster City

About GILD

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.